Elucidate the basic mechanisms underlying aberrant DNA damage and repair in cancer and determine therapeutic vulnerabilities
Discover and integrate signal transduction events regulating tumor-immune cell interactions to expand our understanding of tumor evolution, the immune suppressive tumor microenvironment, and therapy resistance
Determine the causes and consequences of epigenetic dysregulation in cancer and identify novel epigenetic targets for anti-cancer therapy
CBIP Future Directions
Release program-specific RFAs with a focus on collaborative team science, thus promoting collaborations within the program
Facilitate connections with CTOP and CCHE members to create translational research opportunities, enhancing the bench-to-bedside-to-community
Submit Cancer Biology T32 renewal application in September 2024
